US 7838531
Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
granted A61KA61K31/4545A61K31/4709
Quick answer
US patent 7838531 (Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Nov 18 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Department of Health and Human Services
- Grant date
- Tue Nov 23 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 18 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K31/4545, A61K31/4709, A61K45/06, A61P